Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loxoprofen is a nonsteroidal anti-inflammatory drug (NSAID) of the propionic acid derivative class, related to ibuprofen and naproxen. It is primarily indicated for the treatment of pain and inflammation associated with musculoskeletal and joint disorders, as well as rheumatism, soft tissue injury, and other conditions such as headache, toothache, menstrual cramps, neuralgia, and postoperative pain. Loxoprofen acts as a prodrug that is rapidly metabolized in the body to its active trans-alcohol form. The active metabolite functions as a potent non-selective inhibitor of cyclooxygenase (COX), blocking both COX‑1 and COX‑2 isoforms. This inhibition reduces the synthesis of prostaglandins from arachidonic acid—key mediators involved in pain, inflammation, and fever responses[1][2][3][5][6]. Developed originally by Sankyo (now Daiichi Sankyo), it is widely used in Japan and several other countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on loxoprofen.